Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without ...
Hosted on MSN
New cancer treatment could 'change the world' for newly diagnosed head and neck cancer patients
An immunotherapy treatment has been found to ‘change the world’ for head and neck cancer patients by giving them an extra two and a half years before the disease worsens or comes back. During a major ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
PDS0101 and pembrolizumab combination achieved a median overall survival of 39.3 months in HPV16-positive head and neck cancer patients with a CPS of at least 1. The VERSATILE-002 trial showed ...
Scientists have found that preserving lymph nodes during cancer surgery could dramatically improve how patients respond to immunotherapy. The research shows that lymph nodes are essential for training ...
Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 after covering health and science at NPR and NPR affiliate stations. His ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback